摘要
目的 探讨治疗前不同的CA12 5和CA72 -4值对判断宫颈癌的临床分期、病情及预后估测的价值。方法 利用放射免疫分析方法检测 12 5例宫颈癌患者治疗前血清CA12 5 ,CA72 -4值。结果 Ⅳ期宫颈癌患者CA12 5和CA72 -4值明显高于I ,II期。治疗前血清CA12 5 >3 5u/mL预测宫颈癌的灵敏性、特异性分别为 :3 5 .2 %,94%,治疗前血清CA72 -4 >3 .8ng/mL预测宫颈癌的灵敏性、特异性分别为 :2 8.8%,92 %。 结论 CA12 5 >3 5u/mL结合CA72 -4 >3 .8ng/mL可明显提高诊断的灵敏性 ( 4 6.4%)及特异性 ( 94%) ,并对判断宫颈癌的临床分期。
Objective\ Probing the importance of the variety of CA125 and CA72-4 to clinical stages and monitoring the prognosis in cervical cancer. Method We examined serum CA125 and CA72-4 of 125 cases of cervical cancer before therapy by RIA. Result In case of grade Ⅳ, level CA125 and CA72-4 were higher than that in case of grade Ⅰ and Ⅱ. If serum CA125>35u/mL before therapy, the sensitivity and specificity of cervical cancer prediction were 35.2% and 94%, respectively; If pretherapy serum CA72-4>3.8ng/mL, those were 28.8% and 92%. Conclusion\ So in combination of CA125>35u/mL with CA72-4>3.8ng/mL can improve the sensitivity and specificity of diagnosis. The assay of serum CA125 and CA72-4 are worth judging clinical stage and monitoring the prognosis in cervical cancer.
出处
《地方病通报》
2004年第2期30-32,共3页
Endemic Diseases Bulletin
